Finland· FI-REL-REL4810
Magaral
A magaldrate product, registered in Finland by Orion Corporation Orion Pharma. The same ATC class is registered in 6 of our 19 countries.
Checked against Fimea (Finland) on
Informational only — not a medical device.
Where it is registered
Magaldrate is registered in 6 of 19 countries.
Countries holding a registration under ATC A02AD02 (magaldrate), each read from that country’s own register.
- This record: Finland, from Fimea (Finland)
- 4 of them publish a price we can compare per daily dose
Magaldrate · ATC A02AD02
6 / 19 countries
- Belgiumprice
- Finlandprice
- Germany
- Italyprice
- Switzerlandprice
- United Kingdom
Price per daily dose
What a daily dose of magaldrate costs, country by country.
Normalised to the WHO defined daily dose (3.2 g), the median price runs from $0.54 in Italy to $1.43 in Switzerland — a ×2.6 gap.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Magaldrate · price per daily dose (3.2 g)
USD · FX 28 Sept 2026
- CH Switzerland$1.43
- IT Italy$0.54
The record
At a glance
Fimea (Finland)- Manufacturer
- Orion Corporation Orion Pharma
- Country
- Finland (FI)
- ATC code
- A02AD02
- ATC class
- Magaldrate
- Defined daily dose
- 3.2 g, O
- Reimbursed
- Not published by this register
- Source register
- Fimea (Finland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
223 interactions on record for magaldrate.
Graded by severity as the source publishes them — 8 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Magaldrate · interactions on record
223 records
- 8 severe
- 106 moderate
- 93 minor
Most severe, free to view
- RaltegravirJ05AJ01severe
- DolutegravirJ05AJ03severe
- RaltegravirJ05AX08severe
- DolutegravirJ05AX12severe
16 more interactions with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under A02AD02
Magaldrate, as other registers publish it.
- United KingdomBisodol Extra tabletsForest Laboratories UK Ltd
- United KingdomBisodol Heartburn Relief tabletsForest Laboratories UK Ltd
- ItalyGADRALNEOPHARMED GENTILI S.P.A.
- ItalyGADRALNEOPHARMED GENTILI S.P.A.
- ItalyGADRALNEOPHARMED GENTILI S.P.A.
- BelgiumGastricalm 400 mgNovum Pharma
- GermanyMagaldrat RatiopharmRatiopharm Gmbh
- ItalyMAGALDRATO DOCDOC GENERICI S.R.L.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/ff56aca8-fdd3-4f74-a9c5-8da2e49dcb2e GET /v1/drugs/ff56aca8-fdd3-4f74-a9c5-8da2e49dcb2e?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"ddd": null,
"form": "purutabletti",
"route": null,
"ddd_unit": null,
"strength": "800 mg",
"atc_label": "magaldraatti",
"ma_number": "10742",
"auth_status": "Myyntilupa peruuntunut",
"eu_ma_number": null,
"fimea_rel_id": "REL4810",
"authorised_at": "1992-06-24"
}See everything about magaldrate.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.